Cell Therapeutics, Inc. (CTI) to Present at BIO Inve...( SEATTLE Oct. 5 /- Cell Therapeuti...),Health
Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Date:10/5/2007
SEATTLE, Oct. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) management will present at the Biotechnology Industry Organization (BIO) Investor Forum next week.
The conference will be held October 9-11, 2007, at the Palace Hotel in San Francisco. CTI will present on Wednesday, October 10 at 12:45 p.m. (PT). The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at http://www.cticseattle.com.
BIO CEO & Investor Conference
CTI Presentation: Wednesday, October 10
12:45 p.m. Pacific / 3:45 p.m. Eastern
Audio webcast with slides at http://www.cticseattle.com
Investors Contact:
Cell Therapeutics, Inc.
Leah Grant
T: 206.282.7100
F: 206.272.4434
http://www.cticseattle.com/investors.htm
Media Contact:
Cell Therapeutics, Inc.
Dan Eramian
T: 206.272.4343
F: 206.272.4434
Susan Callahan
T: 206.272.4472
F: 206.272.4434
http://www.cticseattle.com/media.htm
'/>"/>
| SOURCE Cell Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
(Date:11/23/2009)....G.Schwade,M.D.announcesthenewlyenhancedCyberKnife...CenterofMiami,( www.cyberknifemiami.com ). ,,...edintensedoseofradiationthatkillscancercellswithno...nlastfrom30minutestoonehour,andisusuallycompletedi...tCenterintheSoutheasternU.S.,theMiamifacilityhasle...
(Date:11/23/2009)... to treatment advances, study finds , , ...ntent of saliva changes as people age, and better ...simple test to diagnose and treat age-related dise...ins numerous proteins that play a role in digestio...ers are trying to find ways to use these proteins ...
(Date:11/23/2009)...the brain is regulated by a peptide known as C3a, ...into nerve cells and is also important for the mig..., reveals new research from the Sahlgrenska Academ...ugh the research has been carried out using mice a... for human beings, which could be given to patient...
(Date:11/23/2009)...partment of Agriculture (USDA) has awarded a two-y...rsity of Minnesota to complete sequencing the geno.... The funding will be used by the Turkey Genome Se...ing using next-generation sequencing platforms, as... functions in the final genome sequence by use of ...
(Date:11/23/2009)...Call/--AnnTaylorStoresCorp.announcedtodaythatitwil...sandGivingcampaign,aholidayfundraisingandawareness...armarksthethirdyearthatAnnTaylor,throughitsANNCARE...mpaignwhereweofferourshoppersanopportunitytohelpsa...hisholidayseason.ClientswhoshopatAnnTaylor,Loft,An...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2[0] CyberKnife Center of Miami Announces New Cancer Patient Treatment Enhancements[0] Quick Saliva Test May One Day Diagnose Diseases[0] New discovery about the formation of new brain cells[0] Turkey Genome Sequencing Consortium awarded $0.9 million from USDA[0] Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year
...600 injuries were reported by the US consumer prod...n previously thought and raising concerns. These ...y are the target market for these wheeled shoes. T...crowded malls and playgrounds.
Scott Wolfson...
... no good reason to deny insurers access to genetic...bate published in this weeks BMJ.
Only if...nformation can we reasonably stop them seeking gen... be able to differentiate premiums according to ve...
...esearch suggests that cannabis, also known as mari...gies and autoimmune disorders that occur when bod...
Researchers led by Andreas Zimmer, at the U....
However, the researchers warned that peo...
... on Thursday received 15 million dollars worth of ...nment to bolster its fight against HIV and AIDS, o...ates will provide Zimbabwe with anti-retroviral dr...US government, which has frosty relations with the...
... TATA company, is in negotiations with Prof Vijay ...ttached to the University of Arkansas, to start p... the final stages. The deal is yet to be finalized...ter (HiDEC) and Neurosurgery Research Programme in...
...llion Euro research project, European Lifestyles a...for Europes four regional seas.
As part o...rom 28 institutions from 15 European countries, fo...oss-cutting environmental issues: habitat change, ...
Other Medicine News:Health News:1,600 Roller Shoe Injuries Reported 2Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Zimbabwe Receives 15m Dollars of AIDS Drugs from US 2Health News:Titan may Produce Glucose Watches Soon 2Health News:Dire Future Predicted for Europe's 4 Seas 2(Date:11/23/2009)..., EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRese...M): Feraheme report,thesecondinamulti-phasesyndi...snewIVironproduct,Feraheme,throughthefirstsixmonth...quantitativeinformationfrom50uniqueNephrologistsan...ssesstrialanduseofFeraheme,obstaclestouse,reasonst...
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonTh...studyofitsleadproduct,PRT-201,inend-stagerenaldise...graft(AVG)creation.TheAVGstudyrepresentsProteon,ss...iouslyannouncingtheinitiationofaPhase1/2studyofPRT...sfistula(AVF)creationearlierthisyear.Proteonalsoan...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-...cedthatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagre...ionoftheproposedmergerbetweenAnesivaandArcionThera...ervotescheduledtotakeplaceatthepreviouslyannounced...ecember3,2009at9:00a.m.PSTat400OysterPoint,Suite10...
Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Brown professor continues debate over recovered memory 50995 1Brown professor continues debate over recovered memory 50995 2Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 1Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 2Fewer Shots Could Still Protect Kids From Pneumonia 50989 1Fewer Shots Could Still Protect Kids From Pneumonia 50989 2[0] Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use[0] Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients[0] Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
... Risk Based on Clinical Data, Preventive Measur...WALTHAM, Mass., July 22 Interleukin Genetics,Inc....nhanced test report,format and information package...test is currently marketed under the brand name Ge...y. The new report will include quantified risk,inf...
...rd Clinical Trial,Service Unit and Epidemiological...generating results of the SEAS trial of ezetimibe ...results from the SHARP and,IMPROVE-IT trials of ez...the relevant regulatory authorities, independently...esting trials (SHARP and IMPROVE-IT) contain about...
Other Medicine Technology:Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 37.75mm diameter Corneal Trephine Blades
6.5mm diameter Corneal Trephine Blades
5.5mm diameter Corneal Trephine Blades
7.50mm Open Trephine Handle
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |